DU
RLAY icon

Delphia (USA)’s Relay Therapeutics RLAY Stock Holding History

Delphia (USA)’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,848
Closed -$212K – 157
2023
Q2 		$212K Buy
16,848
+6,532
+63% +$81.2K 0.33% 149
2023
Q1 		$170K Sell
10,316
-1,883
-15% -$33.8K 0.21% 204
2022
Q4 		$182K Buy
+12,199
New +$233K 0.21% 211

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Delphia (USA)'s RLAY Position: Q3 2023 in Review

Delphia (USA) sold out of Relay Therapeutics (RLAY) in Q3 2023, closing a stake of 16,848 shares — an estimated $212K sold.

Delphia (USA) first reported a position in RLAY in Q4 2022 and held it in 3 quarters. The position peaked at $212K in Q2 2023. 172 funds tracked by Wall St. Rank hold RLAY as of Q3 2023.

  • Delphia (USA) reported no remaining Relay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Delphia (USA) sold 16,848 Relay Therapeutics shares in Q3 2023, an estimated $212K.
  • Delphia (USA) first reported a position in Relay Therapeutics in Q4 2022 and held it in 3 quarters.
  • Delphia (USA)'s Relay Therapeutics position peaked at $212K in Q2 2023.
  • 172 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2023.

Based on Delphia (USA)'s 13F filing for Q3 2023, filed 15 Nov 2023.